Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bingxue Lin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|May 11, 2026
Microenvironment stiffness regulates cell cycleShiqi Gu, Yang Yang, Bingxue Lin, et al.
Acta Diabetologica|November 9, 2022
Bariatric surgery normalizes diabetes risk index by one month post-operationVincent J Sinatra, BingXue Lin, Manish Parikh, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|July 9, 2020
Lipoprotein insulin resistance score in nondiabetic patients with obesity after bariatric surgeryRuina Zhang, BingXue Lin, Manish Parikh, et al.
Anti-Cancer Drugs|March 6, 2021
Cucurbitacin B exhibits antitumor effects on CD133+ HepG2 liver cancer stem cells by inhibiting JAK2/STAT3 signaling pathwayXiaoli Wang, Yudi Bai, Xue Yan, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|May 11, 2026
Microenvironment stiffness regulates cell cycleShiqi Gu, Yang Yang, Bingxue Lin, et al.
Acta Diabetologica|November 9, 2022
Bariatric surgery normalizes diabetes risk index by one month post-operationVincent J Sinatra, BingXue Lin, Manish Parikh, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|July 9, 2020
Lipoprotein insulin resistance score in nondiabetic patients with obesity after bariatric surgeryRuina Zhang, BingXue Lin, Manish Parikh, et al.
Anti-Cancer Drugs|March 6, 2021
Cucurbitacin B exhibits antitumor effects on CD133+ HepG2 liver cancer stem cells by inhibiting JAK2/STAT3 signaling pathwayXiaoli Wang, Yudi Bai, Xue Yan, et al.
Pageof 1